产品说明书

N-Nitrosodiethylamine

Print
Chemical Structure| 55-18-5 同义名 : Diethylnitrosamine;DEN
CAS号 : 55-18-5
货号 : A919866
分子式 : C4H10N2O
纯度 : 99%
分子量 : 102.135
MDL号 : MFCD00013890
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(1028.05 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(979.1 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Diethylnitrosamine (DEN) is a representative chemical carcinogen. DEN induces hepatocarcinogenesis, increasing mitotic hepatocytes and leading to chronic inflammation. Chronic DEN injections lead to liver damage, hepatocytes proliferation, liver fibrosis and cirrhosis, disorganized vasculature, and a modulated immune microenvironment that mimics the usual events observed during human HCC (Hepatocellular carcinoma) development. DEN-induced liver tumors in the rat model shared remarkable molecular characteristics with human HCC, especially with HCC associated with high proliferation[1]. All Cygb(+/-) and Cygb(-/-) mice treated with 25-ppm DEN exhibited liver tumors, compared with 44.4% of their wild-type counterparts. More than 40% of Cygb(-/-) mice developed liver and lung tumors at the nontoxic dose of DEN (0.05 ppm), which did not induce tumors in wild-type mice[2]. gp130 deletion in hepatocytes reduces progression, but not HCC initiation in the DEN model[3]. AR （androgen receptor） protein expression analyses show that DEN causes an initial upregulation of AR in portal fibroblasts and leukocytes, but not hepatocytes, suggesting that hepatocyte-autonomous AR signaling is not essential for DEN-induced carcinogenesis[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

9.79mL

1.96mL

0.98mL

48.95mL

9.79mL

4.90mL

97.91mL

19.58mL

9.79mL
参考文献

[1]Kurma K, Manches O, Chuffart F, Sturm N, Gharzeddine K, Zhang J, Mercey-Ressejac M, Rousseaux S, Millet A, Lerat H, Marche PN, Macek Jilkova Z, Decaens T. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. Cancers (Basel). 2021 Oct 4;13(19):4981

[2]Thuy le TT, Morita T, Yoshida K, Wakasa K, Iizuka M, Ogawa T, Mori M, Sekiya Y, Momen S, Motoyama H, Ikeda K, Yoshizato K, Kawada N. Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice. Am J Pathol. 2011 Aug;179(2):1050-60

[3]Hatting M, Spannbauer M, Peng J, Al Masaoudi M, Sellge G, Nevzorova YA, Gassler N, Liedtke C, Cubero FJ, Trautwein C. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death Dis. 2015 Mar 5;6(3):e1667

[4]Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Sci Rep. 2021 Feb 11;11(1):3646